COVID‐19: vaccination problems

Summary This minireview addresses problems of financing the vaccine development, regulatory questions, the ethics and efficacy of vaccine prioritization strategies and the coverage of variant viruses by current vaccines. Serious adverse effects observed with adenovirus vectored vaccines and mRNA vac...

Full description

Saved in:
Bibliographic Details
Published in:Environmental Microbiology 2021-06, Vol.23 (6), p.2878-2890
Main Author: Brüssow, Harald
Format: Article
Language:English
Subjects:
Clinical trials
COVID-19
COVID-19 vaccines
Disease control
Ethics
Financing
Immunization
Lilliput
mRNA
Placebos
Vaccination
Vaccine development
Vaccines
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary This minireview addresses problems of financing the vaccine development, regulatory questions, the ethics and efficacy of vaccine prioritization strategies and the coverage of variant viruses by current vaccines. Serious adverse effects observed with adenovirus vectored vaccines and mRNA vaccines in mass vaccination campaigns are reported. The ethical problems of continuing with placebo controlled vaccine trials and alternative clinical trial protocols are discussed as well as concrete vaccination issues such as the splitting of doses, the delaying of the second dose, the immunization with two different vaccine types and the need of vaccinating seropositive subjects. Strategies to increase vaccine acceptance in the population are shortly mentioned.
ISSN:1462-2912
1462-2920
DOI:10.1111/1462-2920.15549